Literature DB >> 17393096

Optimal expression condition of recombinant RAP.

Jie Zhang1, Hong Zhang, Hao Bi, Zhiguo Liu, Jianli Guo, Shen Qu.   

Abstract

In order to construct the expression recombinant of human receptor associated protein (RAP), optimize its expression condition and obtain the recombinant protein after expression with high efficiency, two prokaryotic expression vectors-pT7-PL and pET-28a(+) were used to construct the expression recombinant containing RAP cDNA, and the expression efficiency of two kinds of expression E. coli of BL21 strains was compared. The effect of different induction conditions on the expression of recombinant RAP was observed. After recombinant protein was purified with Ni(+) -nitrilotriacetic acid (Ni(+) -NTA) affinity chromatogram, its binding ability with microphage was observed. The results showed that two recombinant plasmids both obtained high expression of RAP. The expression levels of RAP in plasmid pT7-PL-RAP in BL21 (DE3, plysS) strain were significantly higher than in BL21 (DE3) strain. The expression of pT7-PL-RAP in the presence of chloramphenicol was higher than in the absence of chloramphenicol, and most of the inducible expressed RAP was soluble. The RAP which was purified by Ni(+) -NTA resin could strongly bind with the RAW264.7 cells rich in low density lipoprotein receptor (LDLR) family receptors. It was concluded that the expression condition of recombinant RAP was optimized and functional RAP was obtained, which offered a good foundation for the further production of RAP as research tool.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393096     DOI: 10.1007/s11596-007-0102-5

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  8 in total

1.  Rapid isolation of large amount of plasma VLDL and LDL by a two step ultracentrifugation.

Authors:  C B Wang; Y M Feng; Y Q Zong; Y Z Deng; Z C Feng
Journal:  J Tongji Med Univ       Date:  1995

2.  Cellular catabolism of lipid poor apolipoprotein E via cell surface LDL receptor-related protein.

Authors:  Masaaki Narita; David M Holtzman; Anne M Fagan; Mary Jo LaDu; Li Yu; Xianlin Han; Richard W Gross; Guojun Bu; Alan L Schwartz
Journal:  J Biochem       Date:  2002-11       Impact factor: 3.387

3.  Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein.

Authors:  Britto P Nathan; Yanwen Jiang; Gene K Wong; Fei Shen; Gregory J Brewer; Robert G Struble
Journal:  Brain Res       Date:  2002-02-22       Impact factor: 3.252

Review 4.  Role of rap in the biogenesis of lipoprotein receptors.

Authors:  G Bu; M P Marzolo
Journal:  Trends Cardiovasc Med       Date:  2000-05       Impact factor: 6.677

5.  Primary structure of alpha 2-macroglobulin receptor-associated protein. Human homologue of a Heymann nephritis antigen.

Authors:  D K Strickland; J D Ashcom; S Williams; F Battey; E Behre; K McTigue; J F Battey; W S Argraves
Journal:  J Biol Chem       Date:  1991-07-15       Impact factor: 5.157

6.  High affinity binding of receptor-associated protein to heparin and low density lipoprotein receptor-related protein requires similar basic amino acid sequence motifs.

Authors:  L Melman; Z F Cao; S Rennke; M P Marzolo; M R Wardell; G Bu
Journal:  J Biol Chem       Date:  2001-05-29       Impact factor: 5.157

7.  The carboxyl-terminal domain of receptor-associated protein facilitates proper folding and trafficking of the very low density lipoprotein receptor by interaction with the three amino-terminal ligand-binding repeats of the receptor.

Authors:  R Savonen; L M Obermoeller; J S Trausch-Azar; A L Schwartz; G Bu
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

8.  Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals.

Authors:  Karen H Gylys; Jeffrey A Fein; Aiko M Tan; Gregory M Cole
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.